Merck's Stock Surges on Strong Keytruda Demand and Pipeline Progress

Merck's stock has made one of its sharpest monthly advances in recent memory, regaining ground after an extended stretch during which it lagged much of the broader healthcare group.

The rebound has been driven by steady demand for Keytruda, the company's flagship immuno-oncology therapy, encouraging pipeline data, and a broader rotation back toward pharmaceutical names among market participants.

Keytruda continued to anchor overall demand, contributing roughly half of total quarterly sales and reinforcing its role as the company's flagship franchise. The franchise has expanded into additional cancer indications, broadening its addressable patient population.